BR0211336A - Métodos para o tratamento da fibrose do fìgado - Google Patents

Métodos para o tratamento da fibrose do fìgado

Info

Publication number
BR0211336A
BR0211336A BR0211336-8A BR0211336A BR0211336A BR 0211336 A BR0211336 A BR 0211336A BR 0211336 A BR0211336 A BR 0211336A BR 0211336 A BR0211336 A BR 0211336A
Authority
BR
Brazil
Prior art keywords
methods
liver fibrosis
treatment
liver
reducing
Prior art date
Application number
BR0211336-8A
Other languages
English (en)
Inventor
Henry H Hsu
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of BR0211336A publication Critical patent/BR0211336A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"MéTODOS PARA O TRATAMENTO DA FIBROSE DO FìGADO". A presente invenção refere-se a métodos para a redução da fibrose do fígado; métodos para o aumento da função do fígado em um indivíduo que esteja sofrendo de fibrose do fígado; e métodos para a redução da incidência de complicações associadas com a cirrose do fígado. Os métodos de um modo geral envolvem a administração de uma quantidade terapeuticamente eficaz de IFN-<sym>.
BR0211336-8A 2001-07-20 2002-07-09 Métodos para o tratamento da fibrose do fìgado BR0211336A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30701301P 2001-07-20 2001-07-20
PCT/US2002/021813 WO2003007981A1 (en) 2001-07-20 2002-07-09 Methods of treating liver fibrosis

Publications (1)

Publication Number Publication Date
BR0211336A true BR0211336A (pt) 2004-09-28

Family

ID=23187860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211336-8A BR0211336A (pt) 2001-07-20 2002-07-09 Métodos para o tratamento da fibrose do fìgado

Country Status (15)

Country Link
US (1) US20040241138A1 (pt)
EP (1) EP1416953A4 (pt)
JP (1) JP2004535464A (pt)
KR (1) KR20040019069A (pt)
CN (1) CN1549724A (pt)
AR (1) AR047191A1 (pt)
BR (1) BR0211336A (pt)
CA (1) CA2453475A1 (pt)
HU (1) HUP0401156A2 (pt)
IL (1) IL159784A0 (pt)
MX (1) MXPA04000630A (pt)
NO (1) NO20040253L (pt)
PL (1) PL367415A1 (pt)
WO (1) WO2003007981A1 (pt)
ZA (1) ZA200400319B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006084141A2 (en) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc Suspension formulation of interferon
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101974675B1 (ko) 2011-09-16 2019-05-02 갈렉틴 테라퓨틱스, 인크. 비알콜성 지방간염 및 비알콜성 지방간 질환의 치료를 위한 갈락토-람노갈락투로네이트 조성물
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
KR102071739B1 (ko) 2012-06-06 2020-01-30 갈렉틴 테라퓨틱스, 인크. 상승된 유도성 산화 질소 합성효소와 연관된 질환의 치료를 위한 갈락토-람노갈락투로네이트 조성물
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
JP2003510295A (ja) * 1999-09-28 2003-03-18 アマリロ バイオサイエンシズ，インコーポレイテッド 疾患の治療のための低投与量のｉｆｎガンマ
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof

Also Published As

Publication number Publication date
CA2453475A1 (en) 2003-01-30
WO2003007981A1 (en) 2003-01-30
NO20040253L (no) 2004-03-19
US20040241138A1 (en) 2004-12-02
EP1416953A1 (en) 2004-05-12
MXPA04000630A (es) 2005-02-17
HUP0401156A2 (hu) 2004-12-28
EP1416953A4 (en) 2005-11-09
ZA200400319B (en) 2005-03-30
KR20040019069A (ko) 2004-03-04
CN1549724A (zh) 2004-11-24
PL367415A1 (en) 2005-02-21
JP2004535464A (ja) 2004-11-25
IL159784A0 (en) 2004-06-20
AR047191A1 (es) 2006-01-11

Similar Documents

Publication Publication Date Title
BR0211336A (pt) Métodos para o tratamento da fibrose do fìgado
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
AU2002256093A1 (en) Bulking agents as satiety agents
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
TW200740427A (en) Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR9908020A (pt) Fórmula para polimento ótico
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
MXPA02007822A (es) Composicion cosmetica, especialmente para el uso en piel envejecida y/o tensa.
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
BR0107205A (pt) Fixadores cegos e montagem de porca de acionamento
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
MXPA04002009A (es) Composicion farmaceutica que comprende gabapentina o un analogo de la misma y alfa-aminoamida y su uso como analgesico.
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
DE69630527D1 (de) Vorbeugung einer krankheit mit diabetes charakter
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
BR0315495A (pt) Composição para reduzir ingestão calórica
MD2549G2 (ro) Metodă de tratament a hepatitei virale cronice C.
WO2000018353A3 (en) A novel inhibitor of cataract formation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.